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For patients with incurable neurodegenerative disor-
ders such as Huntington’s (HD) and Parkinson’s disease,
cell transplantation has been explored as a potential
treatment option. Here, we present the ﬁrst clinico-
pathological study of a patient with HD in receipt of
cell-suspension striatal allografts who took part in the
NEST-UK multicenter clinical transplantation trial. Using
various immunohistochemical techniques, we found a
discrepancy in the survival of grafted projection neu-
rons with respect to grafted interneurons as well as
major ongoing inﬂammatory and immune responses to
the grafted tissue with evidence of mutant huntingtin
aggregates within the transplant area. Our results indi-
cate that grafts can survive more than a decade post-
transplantation, but show compromised survival with
inﬂammation and mutant protein being observed
within the transplant site.
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Huntington’s disease (HD) is an autosomal-dominantneurodegenerative disorder that presents with a com-
bination of motor, cognitive, and psychiatric problems that
progress over a 20-year period to death. It is currently
incurable, and although many therapies have been the sub-
ject of clinical trials, none have been shown to alter the nat-
ural history of this condition.1 More than 20 years ago,
work commenced on a novel strategy that involved allo-
grafting fetal tissue into the striatum of patients with mid-
stage disease to attempt to repair the damaged circuitry, as
had been shown preclinically using excitotoxic lesions of
the rat and monkey striatum.2 To date, seven small open-
label studies of neural transplants have been conducted
worldwide assessing the feasibility, safety, and tolerability of
this procedure in patients with HD.3–9 This approach has
yielded mixed results including postmortem analysis of
transplanted patients. Here, we present long-term histologi-
cal data on 1 of the 5 patients treated with a fetal striatal
cell suspension allograft as part of the UK study.4
Materials and Methods
Trial Information
This patient was 1 of 5 who were part of the NEST-UK multicen-
ter study, which was initiated in 1998 to evaluate the safety and
efﬁcacy of bilateral fetal striatal transplantation in patients with
mild HD (ISRCTN no 36485475).4 The operations were under-
taken in Cambridge between 2000 and 2003, and this report deals
with patient number 5, the only one to receive bilateral transplants
of fetal striatal tissue in a single operation. The trial was approved
by the Cambridge Regional Ethics Committee (REC ref: 95/086),
as was the postmortem analysis (REC ref:01/117).
Tissue Preparation and Neurosurgical
Procedures
Details of tissue procurement and preparation, immunosuppres-
sion, safety assessment, and implantation have been fully reported
elsewhere.4,10–12 The patient was followed up using the standard
CAPIT-HD protocol.4,5
Postmortem Histological Evaluation
The brain was removed 37.3 hours after death and processed as
described in a previous work.13 Sections were initially prepared for
histochemical analyses to assess graft location, survival, and cyto-
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architecture. For this, one section of each graft was stained for ace-
tylcholinesterase (AChE), as described in a previous publication.16
Immunohistochemistry
For immunohistochemical stainings, the following primary anti-
bodies were used: the neuronal marker microtubule-associated
protein 2 (MAP2; rabbit anti-MAP2; 17490-1-AP, 1:500; Pro-
teintech, Chicago, IL) or neuronal nuclei (NeuN; mouse anti-
NeuN; MAB377, 1:2500; Millipore, Burlington, MA) with the
mutant huntingtin (mHtt) antibody (EM48; MAB5374, 1:500;
Millipore, Burlington, MA). For striatal projection neurons, we
used the calcium-binding protein calbindin (rabbit anti-CB;
Ab11426, 1:1,000; Abcam, Cambridge, MA) and the dopamine-
and cAMP-regulated neuronal phosphoprotein (DARPP-32; rab-
bit anti-DARPP-32; 2306, 1:1,000; Cell Signaling Technology,
Danvers, MA). To identify grafted interneurons, we used calretinin
(rabbit anti-CR; 7699/4, 1:1,000; Swant, Marly, Switzerland),
parvalbumin (mouse anti-PV; P3088, 1:1,000; Sigma-Aldrich,
St. Louis, MO), and choline acetyltransferase (mouse-anti-ChAT;
MAB5270, 1:200; Millipore), as previously described.14 We also
performed a histochemical staining for nicotinamide adenine dinu-
cleotide phosphate (NADPH-d)—a marker for nitric oxide con-
taining striatal interneurons—following previously published
protocols.14,15 The Inﬂammatory/immune response was visualized
using the microglial marker, ionized calcium-binding adaptor mol-
ecule 1 (Iba1; rabbit anti-Iba1; LAK4357, 1:500; Wako Chemi-
cals USA, Richmond, VA), the T-helper cell marker, CD4 (mouse
anti-CD4; NCL-L-CD4-368, 1:500; Leica Microsystems, Wetzlar,
Germany), and the natural killer and cytotoxic T cells, CD8 (mouse
anti-CD8; NCL-L-CD8-4B11, 1:500; Leica Microsystems). Sec-
tions stained for immune cells (CD4 and CD8) were further pre-
treated in a 10-mM sodium citrate buffer solution at 80C for
20 minutes. In some cases, immune cells were also counterstained
with Nissl. Finally, a single immunohistochemistry staining for tyro-
sine hydroxylase (TH; rabbit anti-TH; P40101-150, 1:1,000; Pel
Freeze Biologicals, Rogers, AR) was used to assess the dopaminergic
innervation of the graft. In all cases, sections were incubated with
appropriate secondary antibodies (biotinylated goat antimouse
immunoglobulin G [IgG]; BA9200 1:500; Vector Laboratories,
Burlingame, CA; biotinylated goat antirabbit IgG; BA1000 1:500;
Vector Laboratories) using the ABC Elite Vectastain Kit (Vector
Laboratories).
Image Acquisition and Quantiﬁcation
Brightﬁeld photomicrographs were taken using the Picture
Frame software (MicroBrightField Bioscience, Williston, VT)
attached to an E800 Nikon microscope (Nikon Instruments,
Tokyo, Japan) and prepared for illustration using Adobe Photo-
shop CS5 and ﬁnal ﬁgure panels assembled using Adobe Illustra-
tor CS5 (Adobe Systems, San Jose, CA).
All cell quantiﬁcations were performed on two sections of
the cortex and striatum containing the graft. The perimeters of
the grafted areas were delineated using the tracing contour
option in Stereo Investigator (NeuroExplorer, version 10.0;
MicroBrightField Bioscience) as described in a previous publi-
cation.16 To measure cholinergic activity, images of AChE
stainings were processed with ImageJ software (NIH, Bethesda,
MD) and P-zones, non-P-zones (NP-zones), and the host stria-
tum were individually traced. These areas were measured for
their mean gray values of color intensity.
Statistical Analysis
For all cell quantiﬁcations, an unpaired Student t test was per-
formed using Prism (6.0; GraphPad Software Inc., La Jolla, CA).
Results
Clinical Course
The patient ﬁrst noticed problems in 1995, at the age of
37, with a slight change in his mood and his family
became aware of his problems in 1997 when he developed
nightmares and depression. He had a family history for
HD and went on to have a positive genetic test with an
expansion of 47 CAG repeats in exon 1 of the huntingtin
gene. In 2003, he was selected for neural grafting and
underwent a bilateral transplant procedure without compli-
cations and was followed up according to the CAPIT-HD
protocol until his death in 2015. His clinical history
showed no obvious change in his disease course after graft-
ing, either clinically or on positron emission tomography
imaging, as detailed in a previous work.4
Postmortem Graft Evaluation
Graft Location and Cytoarchitecture. Macroscopically
grafts were easily identiﬁed. In total, six grafts were located
in the left hemisphere with two in the caudate and four in
the putamen (Fig 1A,B0) whereas in the right hemisphere
only one and two grafts were found in these structures
respectively (Fig 1C–E).
General Graft Health. All the typical phenotypes of stria-
tal interneurons were observed within the grafted tissue
including cells positive for calretinin (CR), parvalbumin
(PV), NADPH, and ChAT (Fig 1F–I). They showed
healthy morphologies and extensive dendritic arboriza-
tions. Stereological quantiﬁcations for each of these cell
types revealed similar counts within the transplanted area
in comparison to the host striatum for CR, PV, and
NADPH interneurons (Fig 1F0–I0). Despite rare exam-
ples of healthy MAP2 staining within the graft (Fig 1J),
the presence of DARPP-32–positive cells was almost
exclusively observed within the host striatum (Fig 1K).
Grafted projections neurons, as also identiﬁed with cal-
bindin (CB), were largely necrotic (Fig 1L,L0) and there
were fewer cells within the transplant area. Because of
the tested antibody being discontinued, we used AChE
staining to measure cholinergic enzyme levels within the
P-zones and compared them to the host striatum, where
they looked similar (Fig 1I0).
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FIGURE 1: Graft location, cytoarchitecture and grafted cell survival. Macroscopic identiﬁcation of the transplants based on AChE staining
revealed a total of three grafts in the left hemisphere (delineated by dotted lines): one in the upper caudate nucleus (A,A0) and two in the
putamen (A,A00,B,B0) that occupied between 7.2% and 9.9% of the total striatal area. Cell suspension grafts were observable as clusters
closely resembling P-zones and NP-zones (A,B0). An additional three grafts were located in the right hemisphere (delineated by dotted
lines): one in the caudate nucleus (C) and two in the putamen (D,E) that were much smaller and occupied less than 1.2% of the total
striatal area. Immunohistochemical staining for striatal interneurons included CR, PV, NADPH, and ChAT (F–I). High-power
photomicrographs highlighting the CR (F) and PV (G) staining of cells within a p-zone of the graft as well as examples of grafted neurons
expressing NADPH-d (H), or ChAT (I). All grafted interneurons showed a rather healthy morphology with extensive dendritic arborizations.
Stereological cell counts revealed a similar number of CR- (F0), PV- (G0), NADPH- (H0), and ChAT-immunolabeled (I0) cells in the grafted area
vs the host striatum. Similar immunohistochemical staining approaches were used to identify grafted projection neurons and included
MAP2, DARPP-32, and CB (K–L0). Whereas certain P-zones displayed a restricted number of healthy MAP2 staining cells (J), DARPP-32+
projection neurons were typically absent in the grafted tissue, but frequently found within the host striatum (K). In contrast to
interneurons, detectable CB-immunoreactive projection neurons were largely necrotic (L,L0). Stereological cell counts revealed a striking
difference between the number of MAP2- (J0), DARPP-32- (K0), and CB-immunolabeled (L00) elements in the grafted area vs the host
striatum. Scale bars: A,B,C,D,E = 1.25mm; A0,B0 = 250 μm; A00 = 20 μm; F = 100 μm; G = 250 μm; H,I = 25 μm; J = 25 μm; K = 50 μm;
L = 250 μm; L0 = 50 μm. Abbreviations: AChE = acetylcholinesterase; CB = calbindin; CD = caudate nucleus; ChAT = choline
acetyltransferase; CR = calretinin; DARPP-32 = dopamine- and cAMP-regulated neuronal phosphoprotein; GPi = globus pallidus internal
segment; GPe = globus pallidus external segment; MAP2 = microtubule-associated protein 2; NADPH = nicotinamide adenine
dinucleotide phosphate; PV = parvalbumin; PUT = putamen.
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Inﬂammatory-Immune Response to Cell Suspension
Grafts. A ring of densely packed, maximally hyperactive
microglia surrounded each of the transplanted sites (Fig
2A,B) and was also present within the graft itself.
Throughout this ring, the spectrum of microglial activa-
tion was represented from dystrophic (Fig 2C,D), clus-
tered (Fig 2E) and rod (Fig 2H) cells. Grafted regions
lacking striatal markers (NP-zones) had qualitatively much
lower microglial density, though microglial morphology
and Iba1 intensity remained consistent with a proinﬂam-
matory phenotype (Fig 2F,G). As senescence continues,
these processes become fragmented and severe dystrophy
was conﬁrmed by spherical microglial cell bodies with no
processes, surrounded by small dots of cytoplasm appar-
ently disconnected from the soma (Fig 2I). The outer bor-
ders of the graft contained more dystrophic microglia,
with gnarled, beaded processes (Fig 2J,K). The host tissue,
on the other hand, was almost entirely populated by
dystrophic and nonfunctional microglia. The P-zones con-
tained the highest ratio of ramiﬁed microglia and the few-
est dystrophic cells (Fig 2L), although there were still
many more hyperactive cells than normally present in
healthy tissue.
Graft Innervation and Presence of HD-Related
Pathology
The grafts received modest innervation, as evidenced by
the sparse dopaminergic ﬁbers observed near the trans-
plants (Fig 3A,B). Several mHtt+ aggregates were observed
within the graft site and at the graft/host interface (Fig
3C,D). The mHtt+ aggregates were not only observed
within the extracellular matrix of the grafted area, as previ-
ously reported in solid tissue transplants,16 but they were
also found within cell bodies in the grafts (Fig 3F–H,L).
A particularly interesting observation was that some
mHtt+ aggregates were found along, or even within, the
FIGURE 2: Inﬂammatory response to cell suspension grafts. Series of double immunostainings to visualize inﬂammatory response
to grafted cells. (A,B) Double immunohistochemical staining for Iba1 using nickel-intensiﬁed DAB (microglial cells in black) and
NeuN as revealed using chromogen DAB (neuronal cell in brown) in selected grafts. (B,B0) Representative images of the clear
gradient in microglial response intensity (C) as well as various microglial morphologies within and surrounding the grafts. (C–K)
Higher-power magniﬁcation of grafted areas, showing microglial activation at the graft-host border (C,E), within P-zones (D), NP-
zones (F), clusters of activated cells (G), and host cells (H), illustrating the intensity of the microglial response as well as the
various phenotypes of the activated cells. Proinﬂammatory microglia are identiﬁable by the increased Iba1 reactivity and
shortened process length (E). Highly dystrophic microglia in the host were often missing processes entirely (H) or otherwise
displaying beaded, broken ramiﬁcations (I). Slightly activated microglia (J) and rod cells (K) were present within NP-zones. (L) Pie
charts detailing the percentages of microglial cell populations found at different structures or graft interfaces. Scale bars:
A,B = 1mm; B0 = 50 μm; B00 = 35 μm; C,D,E,I = 30 μm; F = 80 μm; G = 20 μm; H,J,K = 15 μm. DAB = 3,30-diaminobenzidine;
Iba1 = ionized calcium-binding adaptor molecule 1; NeuN = neuronal nuclei.
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dendritic tree of cells within the transplant (Fig 3J,K).
Notably, striatal host cells expressing mHtt+ extended
their dendritic trees into the grafts (Fig 3I,I0).
Finally, groups of T-helper cells (stained for cluster
of differentiation 4 [CD4]; Fig 3M,N) and cytotoxic T
cells (stained for cluster of differentiation 8 [CD8]; Fig
3O–R) were found forming clusters within the grafts,
indicating an ongoing immune and inﬂammatory response
at the time of death. Of signiﬁcance, mHtt, was also iden-
tiﬁed within inﬁltrating T-helper cells (Fig 3R).
Discussion
This is the ﬁrst histological report on striatal cell suspen-
sion allografts originating from the UK NEST striatal
transplantation HD project (NEST-HD).5,17 Postmortem
evaluation revealed that (1) it was easy to ﬁnd striatal
transplants within which grafted interneurons were largely
spared in contrast to the grafted projection neurons that
were rarely observed; (2) there was a striking microglial
response around the graft; (3) there were mHtt aggregates
within the grafted tissue as well as within cells of the
transplanted area and ﬁnally; and (4) there was inﬁltration
of immune cells within the grafted tissue that also con-
tained mHtt, both of which may have further contributed
to poor graft survival. These observations are similar to
those that we have reported previously in HD patients
who receiving solid tissue pieces, but, importantly, there
were notable differences in that we saw a much more
marked inﬁltration of immune cells in the cell suspension
grafts along with more ﬂorid mHtt cellular pathology
within the transplant sites.
This latter observation relating to mHtt expression
within the grafts requires further comment. One could
argue that the cells expressing mHtt within the boundaries
of the grafted areas are host cells that have migrated into
the transplant. Alternatively, one could speculate that
innervation of the grafts by host striatal neurons contain-
ing mHtt+ results in the transport of the pathological pro-
tein from the host to the graft, given that mature striatal
cells have little if any migratory capacity.18 Unfortunately,
the underlying explanation for this ﬁnding cannot be
FIGURE 3: Graft innervation, presence of HD-related pathology, and T-cell response to cell suspension grafts. (A,B) Tyrosine
hydroxylase immunostaining demonstrated modest innervation of the grafts by the dopaminergic system of the host. In some
grafts (C), as well as at the border of the grafts (D), the presence of mHtt was abundant. Within the grafted area, mHtt was
observable both within the extracellular matrix (E,F) and also within the nucleus of a number of cells within the graft site (F–H,
chevrons). In addition to being localized within cell bodies of the host (I,I0), mHtt was observable within (J,K) and along dendritic
paths of cells within the graft or within cells that had a complex arborization (L). Both CD4 (M,N) and CD8 staining (O–R)
revealed clusters of inﬁltrating cells within the grafts and around blood vessels found within the transplants. On rare occasions,
mHtt was observed within CD8+ cells (R). Scale bars: A = 175 μm; B,C = 100 μm; D,I,J,K = 50 μm; E,F,I0,L = 25 μm; G = 35 μm;
H = 20 μm. M,N,O = 60 μm; P = 100 μm; Q = 30 μm; R = 8 μm. Abbreviations: CD4 = cluster of differentiation 4; CD8 = cluster
of differentiation 8; mHtt = mutant huntingtin protein; TH = tyrosine hydroxylase.
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explored in this context, because the technical limitations
inherent to human postmortem analysis do not allow one
to make mechanistic conclusions. Additionally, other
routes of transport should be considered in light of the
fact that mHtt+ was observed, although rarely, within
CD8+ cells. The signiﬁcant inﬁltration of CD4+ and
CD8+ cells, notable within the grafted areas, may have
indeed been facilitated by the more complex and efﬁcient
vascularization that we observed within the cell suspension
grafts (data not shown).
In conclusion, this study again highlights that fetal
striatal allografts can survive long term in the human HD
brain. However, although interneurons within them sur-
vive, projection neurons degenerate, and this is all associ-
ated with inﬂammation around and in the transplant as
well as the expression of mHtt pathology at the graft site.
The relevance and mechanistic consequences of these
observations awaits clariﬁcation, but raises questions as to
whether cell-based approaches for repairing the HD brain
can ultimately repair the dysfunctional networks observed
in this condition.16,19–26
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